Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:10413497rdf:typepubmed:Citationlld:pubmed
pubmed-article:10413497lifeskim:mentionsumls-concept:C0597357lld:lifeskim
pubmed-article:10413497lifeskim:mentionsumls-concept:C0596235lld:lifeskim
pubmed-article:10413497lifeskim:mentionsumls-concept:C0599844lld:lifeskim
pubmed-article:10413497pubmed:issue29lld:pubmed
pubmed-article:10413497pubmed:dateCreated1999-9-15lld:pubmed
pubmed-article:10413497pubmed:abstractTextThe recognition mode of adenophostin A at the D-myo-inositol 1,4, 5-trisphosphate [Ins(1,4,5)P(3)] receptor was investigated. Comparison of conformations of Ins(1,4,5)P(3) and adenophostin A by using the combination of NMR and molecular mechanics (MM) calculations demonstrated that adenophostin A adopted a moderately extended conformation regarding the distance between the 2'-phosphoryl group and the 3' ',4' '-bisphosphate motif, as suggested previously [Wilcox, R. A. et al. (1995) Mol. Pharmacol. 47, 1204-1211]. Based on the nuclear Overhauser effect (NOE) observed between 3'-H and 1' '-H and on MM calculations, the molecular shape of adenophostin A proved to be an extended form at least in solution, in contrast to Wilcox's compactly folded, preliminary hairpin model. GlcdR(2,3',4')P(3), an adenophostin analogue without adenine moiety, was found to be less potent than adenophostin A and almost equipotent to Ins(1,4,5)P(3). We propose the possibility that (i) the optimal spatial arrangement of the three phosphoryl groups and/or (ii) the interaction of the adenine moiety of adenophostin A with the putative binding site, if it exists in the vicinity of the Ins(1,4,5)P(3)-binding site, might account for the exceptional potency of adenophostin A.lld:pubmed
pubmed-article:10413497pubmed:languageenglld:pubmed
pubmed-article:10413497pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10413497pubmed:citationSubsetIMlld:pubmed
pubmed-article:10413497pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10413497pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10413497pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10413497pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10413497pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10413497pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10413497pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10413497pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10413497pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10413497pubmed:statusMEDLINElld:pubmed
pubmed-article:10413497pubmed:monthJullld:pubmed
pubmed-article:10413497pubmed:issn0006-2960lld:pubmed
pubmed-article:10413497pubmed:authorpubmed-author:MurayamaKKlld:pubmed
pubmed-article:10413497pubmed:authorpubmed-author:TakahashiMMlld:pubmed
pubmed-article:10413497pubmed:authorpubmed-author:IwataYYlld:pubmed
pubmed-article:10413497pubmed:authorpubmed-author:TanzawaKKlld:pubmed
pubmed-article:10413497pubmed:authorpubmed-author:KanekoMMlld:pubmed
pubmed-article:10413497pubmed:authorpubmed-author:MiyamotoSSlld:pubmed
pubmed-article:10413497pubmed:authorpubmed-author:KawaseYYlld:pubmed
pubmed-article:10413497pubmed:authorpubmed-author:HotodaHHlld:pubmed
pubmed-article:10413497pubmed:issnTypePrintlld:pubmed
pubmed-article:10413497pubmed:day20lld:pubmed
pubmed-article:10413497pubmed:volume38lld:pubmed
pubmed-article:10413497pubmed:ownerNLMlld:pubmed
pubmed-article:10413497pubmed:authorsCompleteYlld:pubmed
pubmed-article:10413497pubmed:pagination9234-41lld:pubmed
pubmed-article:10413497pubmed:dateRevised2007-7-18lld:pubmed
pubmed-article:10413497pubmed:meshHeadingpubmed-meshheading:10413497...lld:pubmed
pubmed-article:10413497pubmed:meshHeadingpubmed-meshheading:10413497...lld:pubmed
pubmed-article:10413497pubmed:meshHeadingpubmed-meshheading:10413497...lld:pubmed
pubmed-article:10413497pubmed:meshHeadingpubmed-meshheading:10413497...lld:pubmed
pubmed-article:10413497pubmed:meshHeadingpubmed-meshheading:10413497...lld:pubmed
pubmed-article:10413497pubmed:meshHeadingpubmed-meshheading:10413497...lld:pubmed
pubmed-article:10413497pubmed:meshHeadingpubmed-meshheading:10413497...lld:pubmed
pubmed-article:10413497pubmed:meshHeadingpubmed-meshheading:10413497...lld:pubmed
pubmed-article:10413497pubmed:meshHeadingpubmed-meshheading:10413497...lld:pubmed
pubmed-article:10413497pubmed:meshHeadingpubmed-meshheading:10413497...lld:pubmed
pubmed-article:10413497pubmed:meshHeadingpubmed-meshheading:10413497...lld:pubmed
pubmed-article:10413497pubmed:meshHeadingpubmed-meshheading:10413497...lld:pubmed
pubmed-article:10413497pubmed:meshHeadingpubmed-meshheading:10413497...lld:pubmed
pubmed-article:10413497pubmed:meshHeadingpubmed-meshheading:10413497...lld:pubmed
pubmed-article:10413497pubmed:meshHeadingpubmed-meshheading:10413497...lld:pubmed
pubmed-article:10413497pubmed:meshHeadingpubmed-meshheading:10413497...lld:pubmed
pubmed-article:10413497pubmed:year1999lld:pubmed
pubmed-article:10413497pubmed:articleTitleMolecular recognition of adenophostin, a very potent Ca2+ inducer, at the D-myo-inositol 1,4,5-trisphosphate receptor.lld:pubmed
pubmed-article:10413497pubmed:affiliationExploratory Chemistry Research and Biological Research Laboratories, Sankyo Co., Ltd., Tokyo, Japan. hitoda@shina.sankyo.co.jplld:pubmed
pubmed-article:10413497pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10413497lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10413497lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10413497lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10413497lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10413497lld:pubmed